HRP20110456T1 - Derivati indola kao agonisti receptora s1p1 - Google Patents
Derivati indola kao agonisti receptora s1p1 Download PDFInfo
- Publication number
- HRP20110456T1 HRP20110456T1 HR20110456T HRP20110456T HRP20110456T1 HR P20110456 T1 HRP20110456 T1 HR P20110456T1 HR 20110456 T HR20110456 T HR 20110456T HR P20110456 T HRP20110456 T HR P20110456T HR P20110456 T1 HRP20110456 T1 HR P20110456T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- trifluoromethyl
- halogen
- hydrogen
- oxadiazol
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title claims 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title claims 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims abstract 10
- 150000002367 halogens Chemical class 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- -1 trifluoromethoxy, difluoromethoxy Chemical group 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 6
- 125000001424 substituent group Chemical group 0.000 claims abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- NSXLYJQAZFEOGH-UHFFFAOYSA-N 3-[3-chloro-5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)=NO1 NSXLYJQAZFEOGH-UHFFFAOYSA-N 0.000 claims 1
- ISNSOGPOJKUJJB-UHFFFAOYSA-N 3-[4-[5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C=CC2=C1C(N=1)=NOC=1C(SC=1C(F)(F)F)=CC=1C1=CC=CC=C1 ISNSOGPOJKUJJB-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- FAIJSORFUZEUJV-UHFFFAOYSA-N ClC=1C=C(C=CC1OC(C)C)C1=NC(=NO1)C=1C=C2C=CN(C2=CC1)CCC(=O)O.C1(=CC=CC=C1)C=1C=C(SC1C(F)(F)F)C1=NC(=NO1)C=1C=C2C=CN(C2=CC1)CCC(=O)O Chemical compound ClC=1C=C(C=CC1OC(C)C)C1=NC(=NO1)C=1C=C2C=CN(C2=CC1)CCC(=O)O.C1(=CC=CC=C1)C=1C=C(SC1C(F)(F)F)C1=NC(=NO1)C=1C=C2C=CN(C2=CC1)CCC(=O)O FAIJSORFUZEUJV-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625647A GB0625647D0 (en) | 2006-12-21 | 2006-12-21 | Compounds |
| GB0707615A GB0707615D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
| PCT/EP2007/064185 WO2008074821A1 (en) | 2006-12-21 | 2007-12-19 | Indole derivatives as s1p1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110456T1 true HRP20110456T1 (hr) | 2011-07-31 |
Family
ID=39283563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110456T HRP20110456T1 (hr) | 2006-12-21 | 2011-06-17 | Derivati indola kao agonisti receptora s1p1 |
| HRP20120685TT HRP20120685T1 (hr) | 2006-12-21 | 2012-08-29 | Derivati indola kao agonisti receptora s1p1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120685TT HRP20120685T1 (hr) | 2006-12-21 | 2012-08-29 | Derivati indola kao agonisti receptora s1p1 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8101775B2 (no) |
| EP (2) | EP2206710B1 (no) |
| JP (1) | JP5309034B2 (no) |
| KR (1) | KR101495927B1 (no) |
| CN (1) | CN103012390B (no) |
| AR (1) | AR064452A1 (no) |
| AT (1) | ATE509927T1 (no) |
| AU (1) | AU2007336224B2 (no) |
| BR (1) | BRPI0721127A2 (no) |
| CA (1) | CA2673468C (no) |
| CL (1) | CL2007003755A1 (no) |
| CR (2) | CR10922A (no) |
| CY (2) | CY1111702T1 (no) |
| DK (2) | DK2206710T3 (no) |
| DO (1) | DOP2009000133A (no) |
| EA (1) | EA017406B1 (no) |
| ES (1) | ES2389879T3 (no) |
| HK (2) | HK1130255A1 (no) |
| HR (2) | HRP20110456T1 (no) |
| IL (1) | IL199187A (no) |
| JO (1) | JO2701B1 (no) |
| MA (1) | MA30999B1 (no) |
| MX (1) | MX2009006882A (no) |
| MY (2) | MY148470A (no) |
| NO (1) | NO20092385L (no) |
| NZ (1) | NZ577387A (no) |
| PE (2) | PE20121076A1 (no) |
| PL (2) | PL2091949T3 (no) |
| PT (2) | PT2206710E (no) |
| SG (1) | SG177914A1 (no) |
| SI (2) | SI2206710T1 (no) |
| TW (1) | TWI393564B (no) |
| WO (1) | WO2008074821A1 (no) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007236707C1 (en) | 2006-04-03 | 2012-05-24 | Astellas Pharma Inc. | Hetero compound |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| AU2008240773B2 (en) | 2007-04-19 | 2013-10-03 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| US8796318B2 (en) | 2008-05-14 | 2014-08-05 | The Scripps Research Institute | Modulators of sphingosine phosphate receptors |
| WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151626A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| EP2297139A1 (en) * | 2008-06-20 | 2011-03-23 | Glaxo Group Limited | Compounds |
| EA019252B1 (ru) | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| CA2730751A1 (en) * | 2008-07-23 | 2010-01-28 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| RS54970B1 (sr) * | 2008-08-27 | 2016-11-30 | Arena Pharm Inc | Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja |
| WO2010069949A1 (en) * | 2008-12-18 | 2010-06-24 | Merck Serono S.A. | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) * | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| GB0910667D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| WO2011005295A1 (en) * | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| RS61829B1 (sr) | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| US20120283297A1 (en) * | 2009-12-18 | 2012-11-08 | Glaxo Wellcome House | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| JP2013521301A (ja) | 2010-03-03 | 2013-06-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体修飾物質およびその結晶形の調製のためのプロセス |
| CN103119038B (zh) | 2010-04-23 | 2016-05-04 | 百时美施贵宝公司 | 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺 |
| CN103237795B (zh) | 2010-09-24 | 2015-10-21 | 百时美施贵宝公司 | 经取代的噁二唑化合物及其作为s1p1激动剂的用途 |
| EA034451B1 (ru) | 2011-02-07 | 2020-02-10 | Байоджен Ма Инк. | Модуляторы s1p |
| JP6129159B2 (ja) | 2011-05-13 | 2017-05-17 | レセプトス エルエルシー | 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| ES2877686T3 (es) * | 2016-07-22 | 2021-11-17 | Shijiazhuang Sagacity New Drug Dev Co Ltd | Agonista S1P1 y aplicación del mismo |
| CA3038106A1 (en) * | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| CN110627778B (zh) * | 2018-06-25 | 2023-01-24 | 中国科学院上海药物研究所 | 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用 |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| EP4051250A1 (en) | 2019-10-31 | 2022-09-07 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| WO2021160680A1 (en) * | 2020-02-11 | 2021-08-19 | Syngenta Crop Protection Ag | Pesticidally active cyclic amine compounds |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939238A1 (de) | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| CN1788008A (zh) | 2003-05-15 | 2006-06-14 | 麦克公司 | 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑 |
| EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1697333A4 (en) | 2003-12-17 | 2009-07-08 | Merck & Co Inc | 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG) |
| US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| ES2395929T3 (es) | 2005-02-25 | 2013-02-18 | Ono Pharmaceutical Co., Ltd. | Compuestos de indol para tratar trastornos respiratorios |
| WO2006100633A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| WO2006131336A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| KR20080047410A (ko) | 2005-08-23 | 2008-05-28 | 아이알엠 엘엘씨 | 면역억제제 화합물 및 조성물 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP2007262009A (ja) * | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
| AU2007236707C1 (en) * | 2006-04-03 | 2012-05-24 | Astellas Pharma Inc. | Hetero compound |
| ES2400533T3 (es) | 2006-09-07 | 2013-04-10 | Actelion Pharmaceuticals Ltd. | Derivados de piridin 4-ilo como agentes inmunomoduladores |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| AU2008240773B2 (en) * | 2007-04-19 | 2013-10-03 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists |
-
2007
- 2007-12-17 JO JO2007554A patent/JO2701B1/en active
- 2007-12-19 MY MYPI20092612A patent/MY148470A/en unknown
- 2007-12-19 DK DK10158582.6T patent/DK2206710T3/da active
- 2007-12-19 ES ES10158582T patent/ES2389879T3/es active Active
- 2007-12-19 KR KR1020097012841A patent/KR101495927B1/ko not_active IP Right Cessation
- 2007-12-19 EP EP10158582A patent/EP2206710B1/en active Active
- 2007-12-19 CA CA2673468A patent/CA2673468C/en not_active Expired - Fee Related
- 2007-12-19 SG SG2011095114A patent/SG177914A1/en unknown
- 2007-12-19 PT PT10158582T patent/PT2206710E/pt unknown
- 2007-12-19 NZ NZ577387A patent/NZ577387A/en not_active IP Right Cessation
- 2007-12-19 PL PL07857808T patent/PL2091949T3/pl unknown
- 2007-12-19 TW TW096148543A patent/TWI393564B/zh not_active IP Right Cessation
- 2007-12-19 MX MX2009006882A patent/MX2009006882A/es active IP Right Grant
- 2007-12-19 PT PT07857808T patent/PT2091949E/pt unknown
- 2007-12-19 JP JP2009542043A patent/JP5309034B2/ja not_active Expired - Fee Related
- 2007-12-19 CN CN201210396720.5A patent/CN103012390B/zh not_active Expired - Fee Related
- 2007-12-19 WO PCT/EP2007/064185 patent/WO2008074821A1/en active Application Filing
- 2007-12-19 US US12/520,145 patent/US8101775B2/en not_active Expired - Fee Related
- 2007-12-19 PL PL10158582T patent/PL2206710T3/pl unknown
- 2007-12-19 AT AT07857808T patent/ATE509927T1/de active
- 2007-12-19 EA EA200970612A patent/EA017406B1/ru not_active IP Right Cessation
- 2007-12-19 BR BRPI0721127-9A patent/BRPI0721127A2/pt not_active IP Right Cessation
- 2007-12-19 MY MYPI2012004367A patent/MY156822A/en unknown
- 2007-12-19 AR ARP070105729A patent/AR064452A1/es unknown
- 2007-12-19 SI SI200731001T patent/SI2206710T1/sl unknown
- 2007-12-19 EP EP07857808A patent/EP2091949B1/en active Active
- 2007-12-19 DK DK07857808.5T patent/DK2091949T3/da active
- 2007-12-19 SI SI200730670T patent/SI2091949T1/sl unknown
- 2007-12-19 AU AU2007336224A patent/AU2007336224B2/en not_active Ceased
- 2007-12-20 CL CL200703755A patent/CL2007003755A1/es unknown
-
2008
- 2008-01-02 PE PE2012000146A patent/PE20121076A1/es not_active Application Discontinuation
- 2008-01-02 PE PE2008000023A patent/PE20081398A1/es not_active Application Discontinuation
-
2009
- 2009-06-04 IL IL199187A patent/IL199187A/en not_active IP Right Cessation
- 2009-06-05 DO DO2009000133A patent/DOP2009000133A/es unknown
- 2009-06-17 MA MA32003A patent/MA30999B1/fr unknown
- 2009-06-23 NO NO20092385A patent/NO20092385L/no not_active Application Discontinuation
- 2009-07-13 CR CR10922A patent/CR10922A/es unknown
- 2009-10-06 HK HK09109205.3A patent/HK1130255A1/xx not_active IP Right Cessation
- 2009-10-06 HK HK10107189.4A patent/HK1140761A1/xx not_active IP Right Cessation
-
2011
- 2011-06-17 HR HR20110456T patent/HRP20110456T1/hr unknown
- 2011-07-19 CY CY20111100700T patent/CY1111702T1/el unknown
-
2012
- 2012-08-29 HR HRP20120685TT patent/HRP20120685T1/hr unknown
- 2012-09-20 CY CY20121100862T patent/CY1113131T1/el unknown
-
2014
- 2014-07-01 CR CR20140316A patent/CR20140316A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110456T1 (hr) | Derivati indola kao agonisti receptora s1p1 | |
| JP2010513397A5 (no) | ||
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| KR101653229B1 (ko) | 신규한 에스트로겐 수용체 리간드 | |
| NL2000284C2 (nl) | Pyrazine-derivaten. | |
| TWI754397B (zh) | 做為pge2受體調節劑之n-取代吲哚衍生物 | |
| JP2020504753A5 (no) | ||
| TWI691475B (zh) | Ｕｒａｔ１抑制劑 | |
| JP2016135778A (ja) | シアノトリアゾール化合物の医薬用途 | |
| JP2012522847A5 (no) | ||
| JP2013538802A5 (no) | ||
| HRP20140919T1 (hr) | Spojevi koji moduliraju androgene receptore | |
| JP2009504794A5 (no) | ||
| HRP20161116T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3 | |
| JP2016525069A (ja) | シアノトリアゾール化合物 | |
| PE20142294A1 (es) | Compuestos de indol e indazol que activan la ampk | |
| JP2011502148A (ja) | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト | |
| PE20141372A1 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| PE20081472A1 (es) | Compuestos de pirazolina | |
| EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| TW201900178A (zh) | 作為pge2受體調節劑之嘧啶衍生物 | |
| TW201900179A (zh) | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 | |
| CA2727378A1 (en) | New co-crystal compound of rivaroxaban and malonic acid | |
| JP2010516701A5 (no) | ||
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |